Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
Open Access
- 2 October 2008
- Vol. 58 (2), 233-240
- https://doi.org/10.1136/gut.2008.154302
Abstract
Objectives: To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis. Design: A randomised, double-blind, double-dummy, parallel group, multicentre, international, phase III non-inferiority study. Setting: 54 centres in 13 countries. Patients: 380 patients with confirmed diagnosis of established or first attack of ulcerative colitis (clinical activity index (CAI)>4 and endoscopic index ⩾4 at baseline) were randomised and treated. Interventions: 8-week treatment with either 3 g OD or 1 g TID mesalazine granules. Main outcome measures: Clinical remission (CAI⩽4) at study end. Results: 380 patients were evaluable for efficacy and safety by intention-to-treat (ITT); 345 for per protocol (PP) analysis. In the ITT population, 79.1% in the OD group (n = 191) and 75.7% in the TID group (n = 189) achieved clinical remission (pConclusions: OD 3 g mesalazine granules are as effective and safe as a TID 1 g schedule. With respect to the best possible adherence of patients to the treatment, OD dosing of mesalazine should be the preferred application mode in active ulcerative colitis. ClinicalTrials.gov Identifier: NCT00449722Keywords
This publication has 31 references indexed in Scilit:
- Nonadherence in inflammatory bowel disease: Results of factor analysisInflammatory Bowel Diseases, 2007
- MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trialsAlimentary Pharmacology & Therapeutics, 2007
- Medical therapy for ulcerative colitis 2004Gastroenterology, 2004
- Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2003
- Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteersAlimentary Pharmacology & Therapeutics, 2003
- The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamineClinical Gastroenterology and Hepatology, 2003
- Aminosalicylates: potential antineoplastic actions in colon cancer prevention.Scandinavian Journal of Gastroenterology, 2002
- REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic ReviewDigestive Diseases and Sciences, 2002
- Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisThe American Journal of Gastroenterology, 2001
- Adaptive Sample Size Calculations in Group Sequential TrialsBiometrics, 1999